Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

Scand J Rheumatol. 2016;45(2):87-98. doi: 10.3109/03009742.2015.1060259. Epub 2015 Oct 20.

Abstract

The disabling and painful disease osteoarthritis (OA) is the most common form of arthritis. Strong evidence suggests that a subpopulation of OA patients has a form of OA driven by inflammation. Consequently, understanding when inflammation is the driver of disease progression and which OA patients might benefit from anti-inflammatory treatment is a topic of intense research in the OA field. We have reviewed the current literature on OA, with an emphasis on inflammation in OA, biochemical markers of structural damage, and anti-inflammatory treatments for OA. The literature suggests that the OA patient population is diverse, consisting of several subpopulations, including one associated with inflammation. This inflammatory subpopulation may be identified by a combination of novel serological inflammatory biomarkers. Preliminary evidence from small clinical studies suggests that this subpopulation may benefit from anti-inflammatory treatment currently reserved for other inflammatory arthritides.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Biomarkers
  • C-Reactive Protein / immunology
  • Cartilage, Articular / immunology*
  • Cartilage, Articular / pathology
  • Humans
  • Inflammation / immunology
  • Magnetic Resonance Imaging
  • Osteoarthritis / drug therapy
  • Osteoarthritis / immunology*
  • Osteoarthritis / pathology
  • Precision Medicine*
  • Prognosis
  • Synovial Membrane / immunology*
  • Synovial Membrane / pathology
  • Synovitis / drug therapy
  • Synovitis / immunology*
  • Synovitis / pathology

Substances

  • Antirheumatic Agents
  • Biomarkers
  • C-Reactive Protein